Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,87

+0,33

(+6,03%)

Alla chiusura: 07:02PM BST

Capitalizzazione	163,991M
Beta (mensile su 5 anni)	1,51
Rapporto PE (ttm)	N/D
EPS (ttm)	-0,81
Prossima data utili	11 nov 2024 - 15 nov 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	N/D

Tutte

GlobeNewswire
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review perio